Advertisement

MiR-21: A potential new target in the treatment strategy of Crohn's disease?

Published:November 18, 2022DOI:https://doi.org/10.1016/j.dld.2022.11.002
      Recently, an interesting study entitled “MiR-21 regulates epithelial–mesenchymal transition in intestinal fibrosis of Crohn's disease by targeting PTEN/mTOR” was published in Digestive and Liver Disease [
      • Wang Z.
      • Zhou H.
      • Cheng F.
      • Zhang Z.
      • Long S
      MiR-21 regulates epithelial-mesenchymal transition in intestinal fibrosis of Crohn's disease by targeting PTEN/mTOR.
      ]. In this study, the authors revealed that miR-21 was significantly upregulated in the intestinal tissues from Crohn's disease (CD) patients with fibro stenosis. They further showed that miR-21 inhibition with antagonists relieved intestinal fibrosis, which is established by suppressing epithelial–mesenchymal transition (EMT) and regulating extracellular matrix (ECM) remodeling. Their results established and clarified the critical role of miR-21 in CD that may be beneficial in providing a potential therapeutic target against CD. Although this novel discovery opens the door for new treatment of CD, it is not known whether miR-21 inhibition represses the development of CD only by suppressing EMT and regulating ECM remodeling, and whether inhibition of miR-21 could produce unwanted side effects.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wang Z.
        • Zhou H.
        • Cheng F.
        • Zhang Z.
        • Long S
        MiR-21 regulates epithelial-mesenchymal transition in intestinal fibrosis of Crohn's disease by targeting PTEN/mTOR.
        Dig Liver Dis. 2022; ([published online ahead of print, 2022 Apr 30]) (S1590-8658(22)00253-5)https://doi.org/10.1016/j.dld.2022.04.007
        • Xie X.
        • Qu P.
        • Wu H.
        • et al.
        Circulating exosomal miR-21 mediates HUVEC proliferation and migration through PTEN/PI3K/AKT in Crohn's disease.
        Ann Transl Med. 2022; 10: 258https://doi.org/10.21037/atm-22-475
        • Xie X.
        • Liu P.
        • Wu H.
        • et al.
        miR-21 antagonist alleviates colitis and angiogenesis via the PTEN/PI3K/AKT pathway in colitis mice induced by TNBS.
        Ann Transl Med. 2022; 10: 413https://doi.org/10.21037/atm-22-944
        • Dai B.
        • Li H.
        • Fan J.
        • et al.
        MiR-21 protected against diabetic cardiomyopathy induced diastolic dysfunction by targeting gelsolin.
        Cardiovasc Diabetol. 2018; 17 (Published 2018 Sep 4): 123https://doi.org/10.1186/s12933-018-0767-z
        • Maegdefessel L.
        • Azuma J.
        • Toh R.
        • et al.
        MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion.
        Sci Transl Med. 2012; 4: 122ra22https://doi.org/10.1126/scitranslmed.3003441

      Linked Article